Insufficient scRNA-seq data for expression of PYGM at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
brain | 93% | 2013.26 | 2458 / 2642 | 98% | 14.90 | 691 / 705 |
prostate | 91% | 1844.17 | 222 / 245 | 97% | 10.55 | 487 / 502 |
thymus | 66% | 690.81 | 428 / 653 | 67% | 4.50 | 407 / 605 |
uterus | 89% | 1505.67 | 152 / 170 | 29% | 3.71 | 132 / 459 |
bladder | 86% | 2259.62 | 18 / 21 | 22% | 0.91 | 113 / 504 |
muscle | 100% | 276278.71 | 803 / 803 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 100% | 1.75 | 1 / 1 |
blood vessel | 99% | 2614.09 | 1322 / 1335 | 0% | 0 | 0 / 0 |
heart | 96% | 4592.50 | 823 / 861 | 0% | 0 | 0 / 0 |
intestine | 77% | 2195.91 | 743 / 966 | 18% | 0.66 | 93 / 527 |
esophagus | 66% | 2711.92 | 949 / 1445 | 27% | 1.22 | 50 / 183 |
adipose | 79% | 1271.00 | 956 / 1204 | 0% | 0 | 0 / 0 |
adrenal gland | 19% | 142.47 | 49 / 258 | 60% | 2.11 | 138 / 230 |
kidney | 16% | 135.76 | 14 / 89 | 59% | 2.40 | 535 / 901 |
ovary | 32% | 390.61 | 58 / 180 | 40% | 2.42 | 171 / 430 |
breast | 51% | 886.60 | 234 / 459 | 20% | 0.57 | 229 / 1118 |
stomach | 38% | 766.24 | 135 / 359 | 28% | 1.13 | 80 / 286 |
eye | 0% | 0 | 0 / 0 | 49% | 1.14 | 39 / 80 |
pancreas | 1% | 6.39 | 3 / 328 | 46% | 1.18 | 81 / 178 |
spleen | 42% | 342.76 | 102 / 241 | 0% | 0 | 0 / 0 |
peripheral blood | 42% | 864.30 | 392 / 929 | 0% | 0 | 0 / 0 |
lung | 21% | 163.01 | 122 / 578 | 21% | 0.91 | 241 / 1155 |
lymph node | 0% | 0 | 0 / 0 | 31% | 0.49 | 9 / 29 |
tonsil | 0% | 0 | 0 / 0 | 20% | 2.98 | 9 / 45 |
skin | 6% | 169.93 | 102 / 1809 | 13% | 0.28 | 61 / 472 |
liver | 1% | 5.81 | 2 / 226 | 7% | 0.22 | 28 / 406 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0005980 | Biological process | glycogen catabolic process |
GO_0005977 | Biological process | glycogen metabolic process |
GO_0005737 | Cellular component | cytoplasm |
GO_0070062 | Cellular component | extracellular exosome |
GO_0005829 | Cellular component | cytosol |
GO_0102499 | Molecular function | SHG alpha-glucan phosphorylase activity |
GO_0008184 | Molecular function | glycogen phosphorylase activity |
GO_0005515 | Molecular function | protein binding |
GO_0102250 | Molecular function | linear malto-oligosaccharide phosphorylase activity |
GO_0030170 | Molecular function | pyridoxal phosphate binding |
GO_0000166 | Molecular function | nucleotide binding |
Gene name | PYGM |
Protein name | Glycogen phosphorylase, muscle form (EC 2.4.1.1) (Myophosphorylase) Alpha-1,4 glucan phosphorylase (EC 2.4.1.1) |
Synonyms | |
Description | FUNCTION: Allosteric enzyme that catalyzes the rate-limiting step in glycogen catabolism, the phosphorolytic cleavage of glycogen to produce glucose-1-phosphate, and plays a central role in maintaining cellular and organismal glucose homeostasis. . FUNCTION: Allosteric enzyme that catalyzes the rate-limiting step in glycogen catabolism, the phosphorolytic cleavage of glycogen to produce glucose-1-phosphate, and plays a central role in maintaining cellular and organismal glucose homeostasis. . |
Accessions | P11217 ENST00000164139.4 [P11217-1] ENST00000377432.7 [P11217-2] A0A0M4FEM1 |